Through the Director’s Challenge Program of the National Cancer Institute, we have joined with others in an effort to establish a more meaningful classification of lung cancer based on molecular genetic criteria. Specifically, this program has funded our laboratory in developing and implementing the standardized reverse transcription (StaRT) polymerase chain reaction (PCR) method. StaRT-PCR allows numerical, standardized measurement of hundreds of genes to be made simultaneously. Using this method, data from multiple experiments and laboratories may be entered into the same databank, thereby facilitating multi-institutional trials. We have developed software that allows the rapid sorting of data by samples according to annotated criteria and the averaging of the gene expression values among the sorted group of samples. This will enable the establishment of gene expression values for important classes, and this, in turn, will allow the identification of diagnostic criteria.